LONGEVA.

LL-37: adverse events and evidence limits

A synthetic LL-37 trial involved 34 venous-leg-ulcer patients receiving topical treatment or placebo for four weeks. The abstract reports no identified local or systemic safety concern. [1]

The abstract lacks event lists and counts; this does not mean zero events. Topical findings do not establish injectable or systemic-use safety. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Local or systemic safety concerns34 venous-leg-ulcer patients, topical LL-37 or placebo for four weeksThe abstract reports no identified safety concern; it gives no event list or counts — this does not mean zero events; topical findings do not establish injectable or systemic-use safety[1]

References

  1. Alvar Grönberg et al. (2014). Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial https://doi.org/10.1111/wrr.12211.